PDF herunterladen
CC BY 4.0 · World J Nucl Med 2024; 23(04): 227-233
DOI: 10.1055/s-0044-1787733
Original Article

Baseline Ga-68 PSMA PET-Derived Primary Tumor Parameters in Patients with Prostate Cancer and Their Association with Clinical Risk Stratification and Clinicopathologic Features

Özge Vural Topuz
1   Department of Nuclear Medicine, University of Health Sciences, Başakşehir Cam and Sakura City Hospital, Istanbul, Türkiye
,
Ayşegül Aksu
2   Department of Nuclear Medicine, Atatürk Training and Research Hospital, İzmir Kâtip Çelebi University, Izmir, Türkiye
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Aim This article evaluates whether parameters derived from the gallium-68-labeled prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) imaging studies of primary prostate cancer (PCa) lesions were associated with Gleason score (GS), D'Amico risk class, Candiolo nomograms, and the metastatic status of the disease.

Methods We retrospectively evaluated newly diagnosed PCa patients who underwent 68Ga-PSMA PET/CT before therapy. Age, baseline serum prostate-specific antigen (PSA), and metastatic status were recorded. Maximal standardized uptake value (SUVmax), mean SUV (SUVmean), total lesion PSMA (TL-PSMA), and PSMA-derived tumor volume (PSMA-TV) were analyzed. The patients were grouped according to GS (GS ≤ 7 and GS ≥ 8), D'Amico risk classes (low intermediate and high-risk), and also based on their results with the Candiolo nomogram which normally creates five risk classes. For Candiolo classes, very-low risk and low-risk patients were pooled into the low-risk Candiolo (LRC) group, high and very high-risk patients were pooled into the high-risk Candiolo (HRC) group. The intermediate-risk Candiolo group was utilized as-is (IRC).

Results Mean age was 67 ± 8 years, median PSA value was 14.3 (3–211). There were 82 patients with GS ≤ 7 and 38 patients with GS ≥ 8; intermediate D'Amico class comprised 32 patients, while the high D'Amico class comprised 88 patients. For Candiolo, there were 23 LRC, 40 IRC, and 57 HRC patients. PSMA-positive metastases were detected in 44 (36.7%) patients. The SUVmean, SUVmax, PSMA-TV, and TL-PSMA values of the primary tumor demonstrated significant differences when compared according to classifications for GS, D'Amico, LRC versus HRC, and metastatic versus nonmetastatic patients. Of note, TL-PSMA was the only parameter that varied significantly among all risk groups.

Conclusion Primary tumor parameters obtained from baseline 68Ga-PSMA PET/CT are useful to distinguish PCa patients in terms of GS, D'Amico, Candiolo nomogram, and metastatic states. TL-PSMA appears to be the best parameter as it is the only parameter that can distinguish all risk groups from each other.

Keywords

prostate cancer - 68Ga-PSMA PET/CT - Gleason score - D'Amico risk class - Candiolo nomogram


Publikationsverlauf

Artikel online veröffentlicht:
14. Juni 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71 (01) 7-33
    CrossrefPubMedSuche in Google Scholar
  • 2 D'Amico AV, Whittington R, Malkowicz SB. et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17 (01) 168-172
    CrossrefPubMedSuche in Google Scholar
  • 3 Gabriele D, Jereczek-Fossa BA, Krengli M. et al; EUREKA-2 consortium. Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier. Radiat Oncol 2016; 11: 23
    CrossrefPubMedSuche in Google Scholar
  • 4 Vargas HA, Grimm J, F Donati O, Sala E, Hricak H. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol 2015; 25 (05) 1294-1302
    CrossrefPubMedSuche in Google Scholar
  • 5 Hofman MS, Lawrentschuk N, Francis RJ. et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395 (10231): 1208-1216
    CrossrefPubMedSuche in Google Scholar
  • 6 Schmuck S, von Klot CA, Henkenberens C. et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 2017; 58 (12) 1962-1968
    CrossrefPubMedSuche in Google Scholar
  • 7 Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. Grading Committee. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40 (02) 244-252
    CrossrefPubMedSuche in Google Scholar
  • 8 Uprimny C, Kroiss AS, Decristoforo C. et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44 (06) 941-949
    CrossrefPubMedSuche in Google Scholar
  • 9 Koerber SA, Utzinger MT, Kratochwil C. et al. 68 Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med 2017; 58 (12) 1943-1948
    CrossrefPubMedSuche in Google Scholar
  • 10 Onal C, Torun N, Oymak E, Guler OC, Reyhan M, Yapar AF. Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy. Ann Nucl Med 2020; 34 (06) 388-396
    CrossrefPubMedSuche in Google Scholar
  • 11 Topuz ÖV, Aksu A, Erinç SR, Tamam MÖ. Correlations of 68Ga-PSMA PET/CT in the initial staging of prostate cancer patients. Hell J Nucl Med 2021; 24 (01) 60-65
    PubMedSuche in Google Scholar
  • 12 Liu C, Liu T, Zhang N. et al. 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging 2018; 45 (11) 1852-1861
    CrossrefPubMedSuche in Google Scholar
  • 13 Zschaeck S, Andela SB, Amthauer H. et al. Correlation between quantitative PSMA PET parameters and clinical risk factors in non-metastatic primary prostate cancer patients. Front Oncol 2022; 12: 879089
    CrossrefPubMedSuche in Google Scholar
  • 14 Gabriele D, Guarneri A, Bartoncini S. et al. An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by external-beam radiotherapy. Radiat Oncol 2021; 16 (01) 85
    CrossrefPubMedSuche in Google Scholar
  • 15 Utsumi T, Suzuki H, Ishikawa H. et al. External validation of the Candiolo nomogram for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy: a retrospective cohort study. Jpn J Clin Oncol 2022; 52 (08) 950-953
    CrossrefPubMedSuche in Google Scholar
  • 16 Kuten J, Mabjeesh NJ, Lerman H, Levine C, Barnes S, Even-Sapir E. Ga-PSMA PET/CT staging of newly diagnosed intermediate- and high-risk prostate cancer. Isr Med Assoc J 2019; 21 (02) 100-104
    PubMedSuche in Google Scholar